Pharming Group (PHARM.AS) enters the pre-market session on 09 Mar 2026 ahead of its Q4 and FY2025 results due 12 Mar 2026, and investors will watch revenue and guidance closely. Our earnings spotlight flags €1.33 as the current price and €376.00M implied FY2025 revenue in recent reports. This pre-market note frames the numbers, catalysts, and what a surprise could mean for trading on EURONEXT in Europe.
PHARM.AS stock: earnings snapshot
Pharming Group (PHARM.AS) will report fourth-quarter and full-year 2025 results on 12 Mar 2026. The market already prices the stock at €1.33 with a market cap near €926,595,358.00 and volume of 10,536,744.00 shares on the last session. Expect the report to address Ruconest sales, Joenja regulatory updates, and margin trajectory.
What analysts will watch in the Q4 & FY2025 report
Analysts focus on revenue growth, gross margin and guidance. FY2025 preliminary revenue was reported at €376.00M and management’s commentary on Joenja pediatric plans will be key. Also watch R&D and G&A changes after the expense reduction plan announced in 2025. A beat on revenue or clearer guidance could push shares above the 50-day average €1.47.
PHARM.AS financials and valuation
Pharming shows improved cash flow metrics but thin earnings. EPS is -€0.01 and reported PE is -133.00 reflecting near-term losses. Price-to-sales stands at 2.97, price-to-book at 3.90, and current ratio is 3.16. The company reports free cash flow yield near 4.90% and net debt near neutral, supporting operational runway into 2027.
Meyka grade, forecast and model view
Meyka AI rates PHARM.AS with a score out of 100: the model score is 68.86 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 12-month target of €2.04, implying 53.38% upside from €1.33; forecasts are model-based projections and not guarantees.
Technical setup and trading cues
Technicals show momentum loss: RSI 39.76 and CCI -132.76 indicate short-term weakness. Bollinger Bands sit at 1.30–1.45, and the 50-day average is €1.47 versus the 200-day €1.24. Volume trends matter; average volume is 14,503,729.00 and recent sessions traded 10,536,744.00 shares. A strong earnings beat would likely lift RSI and trigger a volume-led move above the 50-day.
Risks and catalysts to watch
Key catalysts include the Q4 results on 12 Mar 2026, regulatory outcomes for Joenja after the FDA CRL, and partnership updates with Novartis or Orchard Therapeutics. Risks include regulatory setbacks, slower RUCONEST growth, and legal inquiries referenced in recent filings. Keep an eye on guidance and management tone on commercialization and cost control.
Final Thoughts
Key takeaways for PHARM.AS stock ahead of the Q4 and FY2025 release: the market is pricing a mixed story at €1.33 with solid cash metrics but minimal EPS. Management’s guidance and regulatory clarity on Joenja will drive the next move. Meyka AI’s forecast model projects €2.04 for the next 12 months, an implied upside of 53.38% versus the current price; this is a model projection, not a guarantee. Traders should watch volume, the 50-day average €1.47, and margin commentary. For longer-term investors, sustained revenue growth and successful regulatory outcomes will be the decisive factors for valuation and a potential re-rating on EURONEXT in Europe. Meyka AI provides this analysis as an AI-powered market analysis platform and the Meyka grade reflects combined fundamental and market signals, not investment advice.
FAQs
When will Pharming (PHARM.AS) report earnings and why does it matter?
Pharming reports Q4 and FY2025 results on 12 Mar 2026. The release matters because it will update revenue, margins, and regulatory progress on Joenja, moving the PHARM.AS stock price and short-term volatility on EURONEXT.
What is Meyka AI’s outlook for PHARM.AS stock?
Meyka AI’s forecast model projects a 12-month target of €2.04, implying about 53.38% upside from €1.33. Forecasts are model-based projections and not guarantees.
What are the main risks investors should monitor?
Main risks include regulatory setbacks for Joenja, disappointing RUCONEST sales, legal actions or investigations, and weaker-than-expected guidance. These could pressure valuation and liquidity on EURONEXT.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)